Belgian biotech Biotalys raises €12M from existing investors
What's the deal? Biotalys, a Belgian crop protection biotech listed on Euronext Brussels, has raised €12.05M ($13.6M) through a private placement backed entirely by existing shareholders. The company issued roughly 7.9 million new shares — about 21% of its outstanding stock — at €1.53 per share, a 40% discount to its 30-day volume-weighted average price.
Investors include Gimv, Ackermans & van Haaren, Sofinnova Industrial Biotech I, the Flemish Institute for Biotechnology (VIB), and several Belgian public investment vehicles such as PMV and the Federal Holding and Investment Company.
Why now? Biotalys develops fermentation-based biological crop protection products designed to replace conventional chemical pesticides. The company is preparing to bring its first products to market in the US and Europe, and it needs capital to advance its pipeline through regulatory and commercialisation milestones.
The timing also reflects growing regulatory and consumer pressure to move away from synthetic chemicals in agriculture — a trend that gives biocontrol companies a tailwind.
What could go wrong? The 40% discount to the share price signals that existing investors demanded significant downside protection, which dilutes current shareholders substantially. The company also appears to lack new external backers, raising questions about broader market appetite for its equity.
Biological crop protection is a notoriously difficult space. Products must clear lengthy regulatory approvals and then prove their efficacy matches cheaper chemical alternatives — a hurdle that has tripped up many biocontrol startups.
The signal: The round underscores a broader pattern in European agtech: companies with deep-science platforms can still secure funding, but increasingly from existing investors rather than new ones. It also reflects a bet that fermentation-based biologicals will become essential infrastructure for sustainable agriculture — a thesis shared by firms like Sofinnova, which has built an entire fund around industrial biotech.
That incumbent investors doubled down, even at a steep discount, suggests conviction in the technology — but also that the path to commercialisation remains long and capital-intensive.
Read more: gimv.com
